Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019[Formula presented]

Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, Himisha Beltran, Anders Bjartell, Alberto Bossi, Alberto Briganti, Rob G. Bristow, Kim N. Chi, Noel Clarke, Ian D. Davis, Johann de Bono, Charles G. Drake, Ignacio Duran, Ros Eeles, Eleni Efstathiou, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Karim FizaziMark Frydenberg, Martin Gleave, Susan Halabi, Axel Heidenreich, Daniel Heinrich, Celestia (Tia) S. Higano, Michael S. Hofman, Maha Hussain, Nicolas James, Ravindran Kanesvaran, Philip Kantoff, Raja B. Khauli, Raya Leibowitz, Chris Logothetis, Fernando Maluf, Robin Millman, Alicia K. Morgans, Michael J. Morris, Nicolas Mottet, Hind Mrabti, Declan G. Murphy, Vedang Murthy, William K. Oh, Piet Ost, Joe M. O'Sullivan, Anwar R. Padhani, Chris Parker, Darren M.C. Poon, Colin C. Pritchard, Robert E. Reiter, Mack Roach, Mark Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver Sartor, Howard I. Scher, Neal Shore, Eric Small, Matthew Smith, Howard Soule, Cora N. Sternberg, Thomas Steuber, Hiroyoshi Suzuki, Christopher Sweeney, Matthew R. Sydes, Mary Ellen Taplin, Bertrand Tombal, Levent Türkeri, Inge van Oort, Almudena Zapatero, Aurelius Omlin

Research output: Contribution to journalArticlepeer-review

43 Scopus citations

Abstract

At the Advanced Prostate Cancer Consensus Conference (APCCC) 2019, 10 important areas of controversy in advanced prostate cancer management were identified and discussed, and experts voted on 123 predefined consensus questions. The full report of the results is summarised here.

Original languageEnglish (US)
Pages (from-to)508-547
Number of pages40
JournalEuropean Urology
Volume77
Issue number4
DOIs
StatePublished - Apr 2020

Bibliographical note

Funding Information:
Although there was a range of opinions regarding the starting dose of chemotherapy in patients of East Asian ethnicity, 60% of panellists recommended starting chemotherapy at a reduced dose. This strategy is supported by the experience of physicians from the Asia-Pacific region and by limited studies. Although no large prospective clinical trials have compared dosing strategies (eg, a reduced dose vs a full dose with G-CSF support) in this population, the available literature suggests that antitumour activity is comparable, even if a reduced dose is used [174,175] .

Publisher Copyright:
© 2020 The Authors

Keywords

  • Advanced prostate cancer
  • Castration-naïve prostate cancer
  • Castration-resistant prostate cancer
  • Genetics
  • High-risk localised prostate cancer
  • Hormone-sensitive prostate cancer
  • Imaging
  • Oligometastatic prostate cancer
  • Overall survival
  • Progression-free survival
  • Prostate cancer treatment
  • Tumour genomic profiling

PubMed: MeSH publication types

  • Consensus Development Conference
  • Journal Article
  • Research Support, Non-U.S. Gov't

Fingerprint

Dive into the research topics of 'Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019[Formula presented]'. Together they form a unique fingerprint.

Cite this